

Supplementary Figure S1. CDK9 kinase inhibitory drug DRB specifically downregulates transcription beyond the SL-dT motif. MCF-7 cells were treated with 25 μM of DRB for 4h and cDNA synthesis was carried out from the isolated mRNA transcripts and subjected to analysis by PCR. Arrows indicate the expected size PCR products. Primers used for PCR were EV-I (Forward:5'AGG GGG ATA AAG GGG TCT CT 3' and Reverse: 5'GAG CCT CCC TAA GTG CAG TG 3') EV-II (Forward:5' TTC AGG TCC TGC AGA AGT CA 3' and Reverse:5'GGG CTT GCT TGG A CTC TAT T3') and EV-IV (Forward:5'GAT CCA GCC AAA CCT GAA AA 3 and Reverse: 5' GCC CAG AGG TGT AAG TCT GC 3'. For Cyclophilin A, we used the same primer set mentioned in materials and methods. PCR condition was 94^0C for 3min, then 94^0C for 30 sec, 56^0C for 1min and 68^0C for 40 sec (40 cycles) followed by 68^0C for 5 min for completion using Taq DNA polymerase (New England Biolab, USA). PCR products (10 μl out of 50μl) were analyzed in 2% agarose gel electrophoresis followed by ethidium bromide staining.



Supplementary Figure S2. ChIP assay detects the enrichment of ERα, CyclinT1 and CDK9 occupancy in the *MYB* transcription attenuation site one hour after estrogen induction. MCF-7 cells were incubated 48h in CSS before addition of 10nM estrogen. Cells were harvested one hour after estrogen treatment and used in ChIP assay with antibodies against ERα, CyclinT1 and CDK9 as mentioned before. Occupancies of all proteins were detected by qPCR using *MYB* intron specific primers and conditions described in the main figures. Amount of binding is represented as percentage input.



Supplementary Figure S3. Effect of Fulvestrant in the expression of endogenous CyclinT1 and CDK9. MCF7 cells were either untreated (-) or treated (+) with 100nM Fulvestrant for 16h and extracts were prepared with RIPA lysis buffer as described in Materials and Methods. 50μg extract was loaded in each well of a SDS-PAGE gel and proteins were detected by western blotting using antibodies against CyclinT1(upper panel), CDK9 (middle panel) and α-Tubulin (lower panel).